ImpriMed: AI-driven Personalized Medicine for Pet Cancer Care

April 20, 2023

Presentation Detail

Speaker
Sungwon Lim, PhD
, CEO & Co-Founder of ImpriMed, Inc.

Synopsis
In this presentation, Dr. Sungwon Lim, CEO & Co-Founder of ImpriMed, shares the latest updates from ImpriMed. ImpriMed continues to improve services to the Veterinary community adding new species and new tumor types to their offerings. Moreover, they continue to make improvements to their AI models to increase prediction power for optimizing the clinical outcomes of individual cancer patients. In a recorded session, Dr. Kevin Choy, a board-certified medical oncologist at Seattle Veterinary Specialists - BluePearl Kirkland, Washington, will present clinical cases of naïve and relapsed Canine lymphoma utilizing ImpriMed's artificial intelligence-driven anticancer drug response predictions.ImpriMed's flagship product, Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed's artificial intelligence (AI) models are trained on real-world clinical outcome data. The models predict the anticancer drugs most likely effective for a particular dog's lymphoma or leukemia based on the individual patient’s information and comprehensive testing of each patient's DNA and live cancer cells.

Presentations

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Veterinary Cancer Society Annual Conference 2023
Learn More →

Canine Lymphoma Diagnostics Past, Present and Future: How AI technology and genetics are pushing the boundaries in veterinary medicine

Veterinary Cancer Society Annual Conference 2023
Learn More →

Impact of AI on clinical practice and outcome

Veterinary Cancer Society Annual Conference 2023
Learn More →

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

Veterinary Cancer Society Annual Conference 2023
Learn More →

Reinventing precision medicine: from dogs to humans

Precision Medicine World Conference 2023
Learn More →

Identification of Novel Predictive Biomarkers of Anticancer Drug Responses in Canine B-Cell Lymphoma Using Targeted NGS

Veterinary Cancer Society Annual Conference 2022
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Annual Conference 2022
Learn More →

Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

ImpriMed Research Update

Veterinary Cancer Society Mid-Year Conference 2022
Learn More →

Precision medicine for pet cancer care

Animal Health, Nutrition and Technology Innovation Europe 2022
Learn More →

Predicting dynamic clinical outcomes of (L-)CHOP chemotherapy for canine lymphoma patients using an artificial intelligence model

Veterinary Cancer Society Annual Conference 2021
Learn More →

ImpriMed: Experiences from the eyes of an oncologist in clinical practice

Veterinary Cancer Society Annual Conference 2021
Learn More →

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Veterinary Cancer Society Annual Conference 2020
Learn More →

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Veterinary Cancer Society Annual Conference 2021
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

World Veterinary Cancer Congress 2020
Learn More →

From dog to human: precision medicine for comparative oncology

Precision Medicine World Conference 2020
Learn More →

ImpriMed: precision medicine for pet cancer care

NYC Oncology Conference 2019
Learn More →

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

Veterinary Cancer Society Annual Conference 2019
Learn More →